These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 37419892)

  • 21. Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancer.
    Yamashita H; Ogiya A; Shien T; Horimoto Y; Masuda N; Inao T; Osako T; Takahashi M; Endo Y; Hosoda M; Ishida N; Horii R; Yamazaki K; Miyoshi Y; Yasojima H; Tomioka N;
    Breast Cancer; 2016 Nov; 23(6):830-843. PubMed ID: 26467036
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gene expression alterations associated with outcome in aromatase inhibitor-treated ER+ early-stage breast cancer patients.
    Thomsen KG; Lyng MB; Elias D; Vever H; Knoop AS; Lykkesfeldt AE; Lænkholm AV; Ditzel HJ
    Breast Cancer Res Treat; 2015 Dec; 154(3):483-94. PubMed ID: 26585578
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of chemokine receptors as potential modulators of endocrine resistance in oestrogen receptor-positive breast cancers.
    Ribas R; Ghazoui Z; Gao Q; Pancholi S; Rani A; Dunbier A; Dowsett M; Martin LA
    Breast Cancer Res; 2014 Oct; 16(5):447. PubMed ID: 25358600
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031.
    Ellis MJ; Suman VJ; Hoog J; Lin L; Snider J; Prat A; Parker JS; Luo J; DeSchryver K; Allred DC; Esserman LJ; Unzeitig GW; Margenthaler J; Babiera GV; Marcom PK; Guenther JM; Watson MA; Leitch M; Hunt K; Olson JA
    J Clin Oncol; 2011 Jun; 29(17):2342-9. PubMed ID: 21555689
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of combining the progesterone receptor and preoperative endocrine prognostic index (PEPI) as a prognostic factor after neoadjuvant endocrine therapy using aromatase inhibitors in postmenopausal ER positive and HER2 negative breast cancer.
    Kurozumi S; Matsumoto H; Inoue K; Tozuka K; Hayashi Y; Kurosumi M; Oyama T; Fujii T; Horiguchi J; Kuwano H
    PLoS One; 2018; 13(8):e0201846. PubMed ID: 30080878
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic significance of preoperative
    Higuchi T; Nishimukai A; Ozawa H; Fujimoto Y; Yanai A; Miyagawa Y; Murase K; Imamura M; Takatsuka Y; Kitajima K; Fukushima K; Miyoshi Y
    Breast; 2016 Dec; 30():5-12. PubMed ID: 27569020
    [TBL] [Abstract][Full Text] [Related]  

  • 27. De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study.
    Guarneri V; Dieci MV; Bisagni G; Frassoldati A; Bianchi GV; De Salvo GL; Orvieto E; Urso L; Pascual T; Paré L; Galván P; Ambroggi M; Giorgi CA; Moretti G; Griguolo G; Vicini R; Prat A; Conte PF
    Ann Oncol; 2019 Jun; 30(6):921-926. PubMed ID: 30778520
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.
    Nishimukai A; Yagi T; Yanai A; Miyagawa Y; Enomoto Y; Murase K; Imamura M; Takatsuka Y; Sakita I; Hatada T; Miyoshi Y
    Clin Breast Cancer; 2015 Jun; 15(3):204-11. PubMed ID: 25600243
    [TBL] [Abstract][Full Text] [Related]  

  • 29. AKT-aro and HER2-aro, models for de novo resistance to aromatase inhibitors; molecular characterization and inhibitor response studies.
    Wong C; Wang X; Smith D; Reddy K; Chen S
    Breast Cancer Res Treat; 2012 Jul; 134(2):671-81. PubMed ID: 22706627
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Overcoming aromatase inhibitor resistance in breast cancer: possible mechanisms and clinical applications.
    Hanamura T; Hayashi SI
    Breast Cancer; 2018 Jul; 25(4):379-391. PubMed ID: 28389808
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of mutational profiles on response of primary oestrogen receptor-positive breast cancers to oestrogen deprivation.
    Gellert P; Segal CV; Gao Q; López-Knowles E; Martin LA; Dodson A; Li T; Miller CA; Lu C; Mardis ER; Gillman A; Morden J; Graf M; Sidhu K; Evans A; Shere M; Holcombe C; McIntosh SA; Bundred N; Skene A; Maxwell W; Robertson J; Bliss JM; Smith I; Dowsett M;
    Nat Commun; 2016 Nov; 7():13294. PubMed ID: 27827358
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Estrogen receptor (ER) mRNA expression and molecular subtype distribution in ER-negative/progesterone receptor-positive breast cancers.
    Itoh M; Iwamoto T; Matsuoka J; Nogami T; Motoki T; Shien T; Taira N; Niikura N; Hayashi N; Ohtani S; Higaki K; Fujiwara T; Doihara H; Symmans WF; Pusztai L
    Breast Cancer Res Treat; 2014 Jan; 143(2):403-9. PubMed ID: 24337596
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design of SERENA-6, a phase III switching trial of camizestrant in
    Turner N; Huang-Bartlett C; Kalinsky K; Cristofanilli M; Bianchini G; Chia S; Iwata H; Janni W; Ma CX; Mayer EL; Park YH; Fox S; Liu X; McClain S; Bidard FC
    Future Oncol; 2023 Mar; 19(8):559-573. PubMed ID: 37070653
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nonhypoxic regulation and role of hypoxia-inducible factor 1 in aromatase inhibitor resistant breast cancer.
    Kazi AA; Gilani RA; Schech AJ; Chumsri S; Sabnis G; Shah P; Goloubeva O; Kronsberg S; Brodie AH
    Breast Cancer Res; 2014 Jan; 16(1):R15. PubMed ID: 24472707
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Close and stable relationship between proliferation and a hypoxia metagene in aromatase inhibitor-treated ER-positive breast cancer.
    Ghazoui Z; Buffa FM; Dunbier AK; Anderson H; Dexter T; Detre S; Salter J; Smith IE; Harris AL; Dowsett M
    Clin Cancer Res; 2011 May; 17(9):3005-12. PubMed ID: 21325071
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cross-talk between ER and HER2 regulates c-MYC-mediated glutamine metabolism in aromatase inhibitor resistant breast cancer cells.
    Chen Z; Wang Y; Warden C; Chen S
    J Steroid Biochem Mol Biol; 2015 May; 149():118-27. PubMed ID: 25683269
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ki67 index changes, pathological response and clinical benefits in primary breast cancer patients treated with 24 weeks of aromatase inhibition.
    Toi M; Saji S; Masuda N; Kuroi K; Sato N; Takei H; Yamamoto Y; Ohno S; Yamashita H; Hisamatsu K; Aogi K; Iwata H; Takada M; Ueno T; Saji S; Chanplakorn N; Suzuki T; Sasano H
    Cancer Sci; 2011 Apr; 102(4):858-65. PubMed ID: 21231986
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increased androgen receptor activity and cell proliferation in aromatase inhibitor-resistant breast carcinoma.
    Fujii R; Hanamura T; Suzuki T; Gohno T; Shibahara Y; Niwa T; Yamaguchi Y; Ohnuki K; Kakugawa Y; Hirakawa H; Ishida T; Sasano H; Ohuchi N; Hayashi S
    J Steroid Biochem Mol Biol; 2014 Oct; 144 Pt B():513-22. PubMed ID: 25178713
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The efficacy of sequential second-line endocrine therapies (ETs) in postmenopausal estrogen receptor-positive and HER2-negative metastatic breast cancer patients with lower sensitivity to initial ETs.
    Iwamoto T; Fujisawa T; Shien T; Araki K; Sakamaki K; Sangai T; Kikawa Y; Takao S; Nishimura R; Takahashi M; Aihara T; Mukai H; Taira N
    Breast Cancer; 2020 Sep; 27(5):973-981. PubMed ID: 32394413
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Possible role of the aromatase-independent steroid metabolism pathways in hormone responsive primary breast cancers.
    Hanamura T; Niwa T; Gohno T; Kurosumi M; Takei H; Yamaguchi Y; Ito K; Hayashi S
    Breast Cancer Res Treat; 2014 Jan; 143(1):69-80. PubMed ID: 24292869
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.